Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814454 | 0.84 | CYP1A2 (0.50) | FOLH1CPA3 | |
| SCHEMBL1818938 | 0.84 | CYP1A2 (0.50) | FOLH1CPA3 | |
| SCHEMBL3471743 | 0.81 | HCAR2 (0.47) | — | |
| SCHEMBL1464853 | 0.81 | FOLH1 (1.00) | FOLH1CPA3 | |
| SCHEMBL1559014 | 0.81 | FOLH1 (1.00) | FOLH1CPA3 | |
| SCHEMBL6171750 | 0.80 | TAAR1 (0.47) | FOLH1 | |
| SCHEMBL28939561 | 0.80 | MME (0.49) | FOLH1 | |
| SCHEMBL27785183 | 0.80 | HCAR2 (0.46) | — | |
| SCHEMBL28696232 | 0.79 | FOLH1 (0.45) | FOLH1CPA3 | |
| SCHEMBL2030081 | 0.78 | KDM6B (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101665-B2 | Process for synthesis of tritiated and deuterated thiorphan and acetorphan | ROCHE PALO ALTO LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101665-B2 | Process for synthesis of tritiated and deuterated thiorphan and acetorphan | ROCHE PALO ALTO LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101665-B2 | Process for synthesis of tritiated and deuterated thiorphan and acetorphan | ROCHE PALO ALTO LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | ROCHE PALO ALTO LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | ROCHE PALO ALTO LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | ROCHE PALO ALTO LLC | 2011-12-29 | — | — | US | disclosed |
| WO-2009077386-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077386-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | NAT1, ZRANB2, TXN | FOLH1 3985/4885CPA3 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.